zlacker

>>giulio+(OP)
>The share of U.S. households reporting at least one user rose from about 11% in late 2023 to more than 16% by mid-2024.

I was wondering how you could get such a high impact overall. But it seems one in 6 households are on GLP-1 drugs in the US.

In my friend circle in Germany I don't even know one single person on this stuff.

It's insane to me that so many people need these to get off the processed foods killing them in the US.

>>carlmr+B5
in europe there is a social stigma around GLP-1 drugs, a lot of people considered it cheating and lazy, so a lot of people don't dare talk about their usage

>>Raed66+e6
The social stigma in Europe exists, because these drugs are in limited supply. So, if a person who does not really need them is using them, the people who actually need them to stay alive might have difficulty accessing them.

>>Foivos+E7
that's actually not true, Mounjaro and Wegovy are pretty much meant for weight loss and there is no competition over them for people with diabetes

>>Raed66+78
Mounjaro is the tirzepatide equivalent to Ozempic (semaglutide) in that it’s prescribed for type 2 diabetes. Wegovy (semaglutide) and Zepbound (tirzepatide) are prescribed for obesity. Otherwise you’re spot on.